Tori Hazel
Gerontology · Altus, OKNPI 1578134979
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,856 of the $4,608 with a category attached, or 83.7%. It is spread thinly across 38 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,247, 6.7 times the $187 reported in 2021.
Across 204 payments — averaging $22.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$775
- Lilly USA, LLC$388
- Johnson & Johnson$351
- Sanofi$314
- Novartis$253
- Pharmacosmos Therapeutics Inc.$208
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,85684%
- Education$75216%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $775 |
| Lilly USA, LLC | 11 | $388 |
| Johnson & Johnson | 10 | $351 |
| Sanofi | 14 | $314 |
| Novartis | 12 | $253 |
| Pharmacosmos Therapeutics Inc. | 11 | $208 |
| Incyte Corporation | 10 | $190 |
| Seagen Inc. | 11 | $189 |
| Sobi, Inc | 8 | $187 |
| Pfizer | 9 | $184 |
| Array Biopharma Inc | 7 | $147 |
| E.r. Squibb & Sons, L.L.C. | 7 | $134 |
| Rigel Pharmaceuticals, Inc. | 6 | $100 |
| Amgen | 6 | $96 |
| Sumitomo Pharma America, Inc. | 4 | $94 |
| Mirati Therapeutics, Inc. | 4 | $89 |
| Eisai Inc. | 5 | $88 |
| Sanofi-aventis U.S. LLC | 1 | $83 |
| ADC Therapeutics America, Inc. | 4 | $82 |
| GSK | 3 | $67 |
| Myriad Genetic Laboratories, Inc. | 4 | $67 |
| Sun Pharmaceutical Industries Inc. | 3 | $64 |
| Myovant Sciences Inc. | 3 | $52 |
| Blueprint Medicines Corporation | 2 | $49 |
| AbbVie | 2 | $45 |
| Astellas Pharma US Inc | 2 | $41 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Stemline Therapeutics Inc. | 2 | $38 |
| AVEO Pharmaceuticals, Inc. | 1 | $26 |
| Genmab U.S., Inc. | 1 | $24 |
| Pharmaessentia USA Corporation | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
| Caris MPI, Inc. | 1 | $20 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
| Coherus Oncology, Inc. | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $16 |
| Dova Pharmaceuticals | 1 | $12 |
How this compares
$4,608 in reported general payments places this provider in the 80th percentile of 73 gerontology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 25 | $393,792 |
| XtandiEnzalutamide | 13 | $177,928 |
| Imatinib Mesylate | 11 | $584 |
| Dexamethasone | 38 | $510 |
| Gabapentin | 29 | $400 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 32 | $399 |
| ValacyclovirValacyclovir Hcl | 20 | $395 |
| Anastrozole | 38 | $357 |
| Hydroxyurea | 30 | $351 |
| Ondansetron OdtOndansetron | 29 | $311 |
| Tamoxifen Citrate | 14 | $224 |
| Levothyroxine Sodium | 18 | $208 |
| Acyclovir | 19 | $141 |
| Prednisone | 17 | $108 |
| Prochlorperazine Maleate | 11 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $16 | $393,79225 claims |
| Astellas Pharma US IncXtandi | $41 | $177,92813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 73 gerontology providers in Oklahoma.
Other gerontology in Altus
- Morgan JohnsAltus$667
- Whitney SimmonsOklahoma City$40K
- Christy CovingtonOklahoma City$12K
- Amanda SpencerNorman$8K
- Shelley TriplettTulsa$7K
- Stacie HanesOklahoma City$6K
- Justin RobertsMuskogee$6K
- Kelly SpychalskiAda$6K
- Samantha TuckerNorman$6K
- Kjerista TiptonTulsa$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.